Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

Biotechnology • Healthcare • Boston, MA, United States • TNGX (NGM)

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

857 320 4900 201 Brookline Avenue, Boston, MA 02215, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Tango Therapeutics (TNGX) Upgraded to Buy: Here's Why - MSN
MSN • Dec 25
Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High? - Yahoo Finance
Yahoo Finance • Nov 21
Stifel initiates Tango Therapeutics stock with Buy rating, $15 price target - Investing.com
Investing.com • Dec 3
Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy (TNGX) - Seeking Alpha
Seeking Alpha • Nov 21
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
MarketBeat • Dec 21

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Tango Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Tango Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Tango Therapeutics, Inc. have?
Tango Therapeutics, Inc. has approximately 155 employees.
What industry is Tango Therapeutics, Inc. in?
Tango Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Tango Therapeutics, Inc. a publicly traded company?
Yes, Tango Therapeutics, Inc. is publicly traded under the ticker symbol TNGX on the NGM. The company has a market capitalization of approximately $1.17 billion.
Where is Tango Therapeutics, Inc. headquartered?
Tango Therapeutics, Inc. is headquartered in Boston, MA, United States at 201 Brookline Avenue, Boston, MA 02215, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.